These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33917265)

  • 1. Successful Direct Acting Antiviral Therapy in Chronic Hepatitis C Normalizes IFNγ and IL2 Production in T Cells Together with TLR8 Expression and Functionality in Peripheral Blood Mononuclear Cells.
    Arias-Loste MT; Cabezas J; Llerena S; Iruzubieta P; San-Segundo D; Merino D; Cuadrado A; Vaqué JP; López-Hoyos M; Crespo J
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33917265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct-acting antiviral therapy enhances total CD4+ and CD8+ T-cells responses, but does not alter T-cells activation among HCV mono-infected, and HCV/HIV-1 co-infected patients.
    Najafi Fard S; Schietroma I; Corano Scheri G; Giustini N; Serafino S; Cavallari EN; Pinacchio C; De Girolamo G; Ceccarelli G; Scagnolari C; Vullo V; d'Ettorre G
    Clin Res Hepatol Gastroenterol; 2018 Sep; 42(4):319-329. PubMed ID: 29279268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased peripheral CD4
    Langhans B; Nischalke HD; Krämer B; Hausen A; Dold L; van Heteren P; Hüneburg R; Nattermann J; Strassburg CP; Spengler U
    J Hepatol; 2017 May; 66(5):888-896. PubMed ID: 28040549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naïve CD4+ T Cell Lymphopenia and Apoptosis in Chronic Hepatitis C Virus Infection Is Driven by the CD31+ Subset and Is Partially Normalized in Direct-Acting Antiviral Treated Persons.
    Auma AWN; Shive CL; Lange A; Damjanovska S; Kowal C; Zebrowski E; Pandiyan P; Wilson B; Kalayjian RC; Canaday DH; Anthony DD
    Front Immunol; 2021; 12():641230. PubMed ID: 33912168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy.
    Llorens-Revull M; Costafreda MI; Rico A; Guerrero-Murillo M; Soria ME; Píriz-Ruzo S; Vargas-Accarino E; Gabriel-Medina P; Rodríguez-Frías F; Riveiro-Barciela M; Perales C; Quer J; Sauleda S; Esteban JI; Bes M
    PLoS One; 2021; 16(7):e0254243. PubMed ID: 34242330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional polymorphisms of TLR8 are associated with hepatitis C virus infection.
    Wang CH; Eng HL; Lin KH; Liu HC; Chang CH; Lin TM
    Immunology; 2014 Apr; 141(4):540-8. PubMed ID: 24205871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired expression and function of TLR8 in chronic HBV infection and its association with treatment responses during peg-IFN-α-2a antiviral therapy.
    Deng G; Ge J; Liu C; Pang J; Huang Z; Peng J; Sun J; Hou J; Zhang X
    Clin Res Hepatol Gastroenterol; 2017 Sep; 41(4):386-398. PubMed ID: 28236535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus lytic infection promotes activation of Toll-like receptor 8 innate immune response in systemic sclerosis monocytes.
    Farina A; Peruzzi G; Lacconi V; Lenna S; Quarta S; Rosato E; Vestri AR; York M; Dreyfus DH; Faggioni A; Morrone S; Trojanowska M; Farina GA
    Arthritis Res Ther; 2017 Feb; 19(1):39. PubMed ID: 28245863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses.
    Aregay A; Owusu Sekyere S; Deterding K; Port K; Dietz J; Berkowski C; Sarrazin C; Manns MP; Cornberg M; Wedemeyer H
    J Hepatol; 2019 Nov; 71(5):889-899. PubMed ID: 31295532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic scars in regulatory T cells are retained after successful treatment of chronic hepatitis C with direct-acting antivirals.
    Kim SY; Koh JY; Lee DH; Kim HD; Choi SJ; Ko YY; Lee HS; Lee JS; Choi IA; Lee EY; Jeong HW; Jung MK; Park SH; Park JY; Kim W; Shin EC
    J Hepatol; 2024 Nov; 81(5):806-818. PubMed ID: 38879170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral PD-1
    Romani S; Stafford K; Nelson A; Bagchi S; Kottilil S; Poonia B
    Front Immunol; 2019; 10():1470. PubMed ID: 31316516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Chronic Hepatitis C Infection, Myeloid-Derived Suppressor Cell Accumulation and T Cell Dysfunctions Revert Partially and Late After Successful Direct-Acting Antiviral Treatment.
    Telatin V; Nicoli F; Frasson C; Menegotto N; Barbaro F; Castelli E; Erne E; Palù G; Caputo A
    Front Cell Infect Microbiol; 2019; 9():190. PubMed ID: 31259160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased CD4
    Wei K; Jiang BC; Guan JH; Zhang DN; Zhang MX; Wu JL; Zhu GZ
    Viral Immunol; 2018 Oct; 31(8):559-567. PubMed ID: 30067145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus core protein triggers expansion and activation of CD4(+)CD25(+) regulatory T cells in chronic hepatitis C patients.
    Zhai N; Chi X; Li T; Song H; Li H; Jin X; Crispe IN; Su L; Niu J; Tu Z
    Cell Mol Immunol; 2015 Nov; 12(6):743-9. PubMed ID: 25531392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunology of HCV infection: the causes of impaired cellular immune response and the effect of antiviral treatment].
    Pár G; Berki T; Pálinkás L; Balogh P; Szereday L; Halász M; Szekeres-Barthó J; Miseta A; Hegedus G; Mózsik G; Hunyady B; Pár A
    Orv Hetil; 2006 Apr; 147(13):591-600. PubMed ID: 16623441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function.
    Serti E; Chepa-Lotrea X; Kim YJ; Keane M; Fryzek N; Liang TJ; Ghany M; Rehermann B
    Gastroenterology; 2015 Jul; 149(1):190-200.e2. PubMed ID: 25754160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin.
    Perrella A; Sbreglia C; Atripaldi L; Esposito C; D'Antonio A; Perrella O
    Scand J Gastroenterol; 2010; 45(2):250-5. PubMed ID: 19968615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis.
    Comarmond C; Garrido M; Pol S; Desbois AC; Costopoulos M; Le Garff-Tavernier M; Si Ahmed SN; Alric L; Fontaine H; Bellier B; Maciejewski A; Rosenzwajg M; Klatzmann D; Musset L; Poynard T; Cacoub P; Saadoun D
    Gastroenterology; 2017 Jun; 152(8):2052-2062.e2. PubMed ID: 28274850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TLR8-mediated activation of human monocytes inhibits TL1A expression.
    Saruta M; Michelsen KS; Thomas LS; Yu QT; Landers CJ; Targan SR
    Eur J Immunol; 2009 Aug; 39(8):2195-202. PubMed ID: 19637197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased IFNγ production correlates with diminished production of cytokines by dendritic cells in patients infected with hepatitis C virus and receiving therapy.
    Hammond T; Lee S; Watson MW; Flexman JP; Cheng W; Price P
    J Viral Hepat; 2011 Jul; 18(7):482-92. PubMed ID: 20529204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.